David McMullin is Chief Commercial Officer at Aldeyra Therapeutics, Inc. (ALDX). They have made 1 open-market trade across 1 company since 2019, most recently 2020-03-02.
CIK 0001738662
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $20K since 2019, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ALDX | 255,183 | $156K |
Shares reported on the most recent Form 4, priced at the 2020-03-06 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ALDX | BUY | 2019-09-05 | 2019-09-09 | $4.68 | $20K | +14.1% | +2.6% | -4.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.